AbbVie Says Health Canada Approves Skyrizi For Moderate To Severe Plaque Psoriasis In Patients Aged 6 To Under 18
Share
Why It Matters
AbbVie got approval to sell Skyrizi to kids and teens with psoriasis. This means the company can now reach younger patients and grow that medicine's sales.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.